Sign inJoin waitlistJoin the waitlist

Nathan Bahary

Program Director · Allegheny Health Network Medical Education Consortium

Credentials: · · · · ·

History

Allegheny Health Network Medical Education Consortium
Present
Allegheny Health Network Medical Education Consortium
Present
Division Chief of Medical Oncology and Director of AHNCI Clinical Research · Allegheny Health Network Medical Education Consortium
Present

Medical Oncology
1992–1994
Internal Medicine
1989–1992
Doctor of Medicine
1985–1989

Research

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
New England Journal of Medicine · 2013 · 5,446 citations
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Journal of Clinical Oncology · 2015 · 478 citations
The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis
Developmental Biology · 1998 · 428 citations

Herbert Zeh
52 papers
Amer Zureikat
49 papers
Aatur Singhi
39 papers · 19 as a fellow
Melissa Hogg
28 papers · 1 as a fellow
David Bartlett
25 papers
Kenneth Lee
25 papers
Alessandro Paniccia
20 papers · 20 as a resident
Randall Brand
19 papers
Brian Boone
13 papers · 5 as a fellow
Leonard Zon
13 papers
Marina Nikiforova
11 papers
Rudolph Leibel
11 papers

Grants

Multiplex Inducible Trangenesis in the Zebrafish
National Institute of Child Health and Human Development · R01
Contact PI · $1.6M · University of Pittsburgh at Pittsburgh
2007–2012
Modeling Novel Gastrointestinal Growth Pathways in the Zebrafish
National Institute of Diabetes and Digestive and Kidney Diseases · R21
Contact PI · $403.2K · University of Pittsburgh at Pittsburgh
2006–2010
Developmental Biology of Hematopoiesis
National Heart, Lung, and Blood Institute · K08
Contact PI · $551.2K · Dana-Farber Cancer Inst
1998–2002

Clinical trials

Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer
Principal investigator · Terminated · Phase 2
Nathan Bahary, MD
2017–2019
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
Principal investigator · Completed · Phase 1
Inovio Pharmaceuticals
2014–2018
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Principal investigator · Completed · Phase 2
Nathan Bahary, MD
2014–2018
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Principal investigator · Completed · Phase 1
Kyntra Bio
2008–2014